A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07519356

Enrollment

9000

Registered

2026-04-09

Start date

2022-06-09

Completion date

2030-12-30

Last updated

2026-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoproliferative Disease

Brief summary

The primary objective of this study is to assess the 10-year overall survival (OS) of patients with different lymphoproliferative disorders. Secondary objectives include evaluating the comorbidities and fitness of patients and their impact on treatment choices and outcomes. Additionally, the study will examine the effectiveness of various therapeutic regimens, with a particular focus on new treatments, such as chemo-free protocols, targeted drugs, and cell therapies, in order to determine the best treatment sequence for refractory and relapsed cases. The research will also investigate how clinical and biological factors influence disease progression or relapse. Another aim is to explore potential correlations between genotype, clinical phenotype, and outcomes, both at diagnosis and during various disease stages. The study will also assess the incidence of tumor lysis syndrome and other adverse events during treatment, considering how these factors might affect treatment discontinuations or dose reductions. Another objective is to evaluate the outcomes of patients who are managed with a "watch and wait" approach. Long-term toxicities and the occurrence of secondary malignancies will also be studied, alongside the analysis of healthcare costs and the resources used in patient management.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients ≥ 18 years diagnosed with and/or treated for lymphoproliferative disorders. * Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document * Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease

Exclusion criteria

* Patients who are unable to understand informed consent document

Design outcomes

Primary

Measure	Time frame
To evaluate 10 year overall survival (OS) of each lymphoproliferative disorder.	from 2002 to 2030

Countries

Italy

Contacts

CONTACTLuca Arcaini

l.arcaini@smatteo.pv.it0382501284

Outcome results